Send to

Choose Destination
JAMA Oncol. 2019 Jan 1;5(1):74-82. doi: 10.1001/jamaoncol.2018.4224.

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.

Author information

Bloomberg-Kimmel Institute for Cancer Immunotherapy, Department of Oncology, Johns Hopkins University, Baltimore, Maryland.
now with Department of Medicine and UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh.
Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain.
Department of Medicine (Oncology), Yale Cancer Center, New Haven, Connecticut.
Comprehensive Cancer Centers of Nevada, University of Nevada Las Vegas School of Medicine, Las Vegas.
The Angeles Clinic and Research Institute, Los Angeles, California.
Department of Medicine,Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Medicine, Hematology/Oncology, Massachusetts General Hospital, Boston.
Section of Hematology/Oncology, University of Chicago, Chicago, Illinois.
Department of Medical Oncology, Centre Léon-Bérard, Lyon, France.
Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.
HonorHealth Research Institute, Scottsdale, Arizona.
Ventana Medical Systems, Inc, Tucson, Arizona.
Genentech, Inc, South San Francisco, California.
now with Bellicum Pharmaceuticals, Inc, South San Francisco, California.
Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, England.



Atezolizumab (anti-programmed cell death ligand 1 [PD-L1]) is well tolerated and clinically active in multiple cancer types. Its safety and clinical activity in metastatic triple-negative breast cancer (mTNBC) has not been reported.


To evaluate the safety, clinical activity, and biomarkers associated with the use of single-agent atezolizumab in patients with mTNBC.

Design, Setting, and Participants:

Women with mTNBC (defined by investigator assessment) were enrolled between January 2013 and February 2016 in a multicohort open-label, phase 1 study at US and European academic medical centers. Median follow-up was 25.3 months (range, 0.4-45.6 months). Eligible patients regardless of line of therapy had measurable disease by Response Evaluation Criteria in Solid Tumors, version 1.1; Eastern Cooperative Oncology Group performance status of 0 to 1; and a representative tumor sample for assessment of immune cell (IC) PD-L1 expression.


Atezolizumab was given intravenously every 3 weeks until unacceptable toxic effects or loss of clinical benefit.

Main Outcomes and Measures:

Primary outcome was safety and tolerability. Activity and exploratory outcomes included objective response rate (ORR), duration of response, progression-free survival (PFS), and overall survival (OS). Outcomes were assessed in all patients and in key patient subgroups.


Among 116 evaluable patients (median age, 53 years [range, 29-82 years]), treatment-related adverse events occurred in 73 (63%); 58 (79%) were grade 1 to 2. Most adverse events occurred within the first treatment year. The ORRs were numerically higher in first-line (5 of 21 [24%]) than in second-line or greater patients (6 of 94 [6%]). Median duration of response was 21 months (range, 3 to ≥38 months). Median PFS was 1.4 (95% CI, 1.3-1.6) months by RECIST and 1.9 (95% CI, 1.4-2.5) months by irRC. In first-line patients, median OS was 17.6 months (95% CI, 10.2 months to not estimable). Patients with PD-L1 expression of at least 1% tumor-infiltrating ICs had higher ORRs and longer OS (12% [11 of 91]; 10.1 [95% CI, 7.0-13.8] months, respectively) than those with less than 1% ICs (0 of 21; 6.0 [95% CI, 2.6-12.6] months, respectively). High levels of ICs (>10%) were independently associated with higher ORRs and longer OS.

Conclusions and Relevance:

Single-agent atezolizumab was well tolerated and provided durable clinical benefit in patients with mTNBC with stable or responding disease and in earlier lines of treatment.

Trial Registration: identifier: NCT01375842.

[Available on 2019-09-13]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center